查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576809

整體焦慮症市場：按作用機制、定價策略、分銷管道和醫療保健提供者分類 - 2025-2030 年全球預測

Generalized Anxiety Disorder Market by Mode Of Action (Gamma-Aminobutyric Acid Receptors, Norepinephrine Modulators, Serotonin Modulators), Pricing Strategy, Distribution Channel, Healthcare Providers - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年整體焦慮症市場價值為21.3億美元，預計到2024年將達到22.3億美元，複合年成長率為5.42%，預計到2030年將達到30.9億美元。

整體焦慮症（GAD）是一種慢性精神疾病，其特徵是對日常生活各個方面過度且無法控制的擔憂，影響著全世界數百萬人。其市場範圍包括旨在管理和緩解症狀的藥品、行為健康服務和數位心理健康平台。人們對心理健康問題的認知不斷提高，盛行率不斷上升，因此需要有效的治療，而經濟不確定性和 COVID-19 大流行等全球壓力因素又加劇了這個問題。應用範圍從處方藥到認知行為療法，再到提供診斷和治療支援的數位應用。最終使用者群體主要是青少年和成人，人們對兒科病例中廣泛性焦慮症的認知不斷提高。影響該市場的關鍵成長要素包括個人化醫療的進步、新興的遠距遠端醫療產業以及消費者對正念和健康應用程式等非藥物干預措施的強勁需求。開發綜合治療通訊協定和使用人工智慧進行個人化治療方法存在潛在機會。然而，該市場面臨一些限制，例如圍繞心理健康的恥辱、治療結果不一致以及可及性問題，特別是在低度開發地區。一個關鍵的挑戰是確保監管部門的核准並遵守嚴格的健康指南。創新成長領域包括增強數位診斷工具、擴展人工智慧主導的治療進展見解以及利用基因組學進行更有針對性的治療。市場的本質是動態的，需要不斷發展和適應新技術進步和整體護理模式。企業應專注於加強與醫療技術公司的合作，並擴大遠端醫療服務，以解決醫療保健取得問題。此外，透過宣傳活動提高公眾意識和減少恥辱感也在市場擴張中發揮重要作用。透過優先考慮這些策略，公司可以有效地應對現有挑戰，同時利用不斷成長的需求。

主要市場統計
基準年[2023] 21.3億美元
預測年份 [2024] 22.3億美元
預測年份 [2030] 30.9億美元
複合年成長率（%） 5.42%

市場動態：快速發展的整體焦慮症市場的關鍵市場洞察

供需的動態交互作用正在改變整體焦慮症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 遠端醫療和遠距精神病學服務的擴展將促進整體焦慮症的便捷治療。
    • 政府的舉措和對心理健康計畫的資助推動了市場成長
    • 透過將行為和心理療法整合到治療方法中來改善患者的治療效果
    • 加強製藥公司和研究機構之間的合作以開發先進的治療方法
  • 市場限制因素
    • 有限的保險範圍和報銷問題影響了整體焦慮症的治療
  • 市場機會
    • 由於整體焦慮症藥物治療方法的進步，市場潛力巨大
    • 探索針對焦慮症的正念和認知行為治療應用程式
    • 對心理健康意識宣傳活動的投資增加推動了焦慮相關產品的市場成長
  • 市場挑戰
    • 圍繞心理健康狀況的社會恥辱影響患者的診斷和尋求治療的行為

波特的五力：駕馭整體焦慮症市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解整體焦慮症市場的外部影響

外部宏觀環境因素在塑造整體焦慮症市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解整體焦慮症市場的競爭格局

整體焦慮症市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV整體焦慮症市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估整體焦慮症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了整體焦慮症市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對整體焦慮症市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 遠端醫療和遠距精神病學服務的擴展有利於整體焦慮症的便捷治療
      • 政府的舉措和對心理健康計畫的資助推動了市場成長
      • 將行為和心理治療納入治療計劃，以改善患者的治療效果
      • 加強製藥公司與研究機構的合作，開發先進的治療方法
    • 抑制因素
      • 保險範圍限制和報銷問題限制了整體焦慮症治療的機會
    • 機會
      • 由於整體焦慮症藥物治療的進展，預計會有較高的市場銷路
      • 焦慮症正念和認知行為治療應用程式的調查
      • 對心理健康意識宣傳活動的投資增加推動了焦慮相關產品的市場成長
    • 任務
      • 圍繞精神疾病的社會恥辱影響患者的診斷和尋求治療的行為
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章整體焦慮障礙的市場機制

  • γ-胺基丁酸 (GABA) 受體
  • 去甲腎上腺素調節劑
  • 血清素調節劑

第7章整體焦慮症市場價格策略

  • 經濟艙票價
  • 滲透定價
  • 溢價

第8章整體焦慮症市場：按分銷管道

  • 醫院
  • 網路藥房
  • 零售藥房

第9章醫療保健專業人員的整體焦慮症市場

  • 基層醫療醫生
  • 精神科醫生
  • 治療師

第10章：美洲整體焦慮症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太整體焦慮症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的整體焦慮症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C03B0

The Generalized Anxiety Disorder Market was valued at USD 2.13 billion in 2023, expected to reach USD 2.23 billion in 2024, and is projected to grow at a CAGR of 5.42%, to USD 3.09 billion by 2030.

Generalized Anxiety Disorder (GAD) is a chronic mental health condition characterized by excessive and uncontrollable worry about various aspects of daily life, affecting millions worldwide. Its market scope encompasses pharmaceuticals, behavioral therapy services, and digital mental health platforms designed to manage and alleviate symptoms. The necessity for effective treatments stems from the heightened awareness and rising prevalence of mental health issues, amplified by global stressors such as economic uncertainties and the COVID-19 pandemic. Applications are manifold, ranging from prescription medications to cognitive-behavioral therapy and digital applications that offer diagnostic and therapeutic support. End-use demographics primarily include adolescents and adults, with a growing recognition of GAD in pediatric cases. Key growth factors influencing this market include advancements in personalized medicine, the burgeoning telehealth sector, and strong consumer demand for non-pharmacological interventions such as mindfulness and wellness apps. The potential opportunities exist in developing integrated treatment protocols and harnessing AI for personalized treatment regimens. However, the market faces limitations such as stigma surrounding mental health, inconsistent treatment efficacy, and accessibility issues, particularly in underdeveloped regions. A significant challenge is ensuring regulatory approvals and compliance with stringent health guidelines. Innovative areas for growth include the enhancement of digital diagnostic tools, expansion of AI-driven insights for therapeutic advancements, and leveraging genomics for better-targeted treatments. The nature of the market is dynamic, necessitating constant evolution and adaptation to emerging technological advances and holistic care models. Companies should focus on fostering collaborations with health-tech firms and expanding teletherapy offerings to address care accessibility issues. Additionally, increasing public awareness and reducing stigma through campaigns can play a critical role in market expansion. By prioritizing these strategies, businesses can capitalize on the growing demand while addressing existing challenges effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 2.13 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.09 billion
CAGR (%) 5.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of telemedicine and telepsychiatry services facilitating convenient treatment for generalized anxiety disorder
    • Government initiatives and funding for mental health programs boosting market growth
    • Integration of behavioral therapies and psychotherapies in treatment regimens enhancing patient outcomes
    • Increasing collaborations between pharmaceutical companies and research institutions to develop advanced treatments
  • Market Restraints
    • Limited insurance coverage and reimbursement issues affecting access to generalized anxiety disorder treatments
  • Market Opportunities
    • Advancements in pharmacological treatments for generalized anxiety disorder yielding high market potential
    • Exploration of mindfulness and cognitive-behavioral therapy apps targeting anxiety disorders
    • Increasing investment in mental health awareness campaigns driving market growth in anxiety-related products
  • Market Challenges
    • Social stigma surrounding mental health conditions impacting patient diagnosis and treatment-seeking behavior

Porter's Five Forces: A Strategic Tool for Navigating the Generalized Anxiety Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generalized Anxiety Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generalized Anxiety Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generalized Anxiety Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generalized Anxiety Disorder Market

A detailed market share analysis in the Generalized Anxiety Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generalized Anxiety Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generalized Anxiety Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generalized Anxiety Disorder Market

A strategic analysis of the Generalized Anxiety Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generalized Anxiety Disorder Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Generalized Anxiety Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mode Of Action, market is studied across Gamma-Aminobutyric Acid (GABA) Receptors, Norepinephrine Modulators, and Serotonin Modulators.
  • Based on Pricing Strategy, market is studied across Economy Pricing, Penetration Pricing, and Premium Pricing.
  • Based on Distribution Channel, market is studied across Hospitals, Online Pharmacies, and Retail Pharmacies.
  • Based on Healthcare Providers, market is studied across Primary Care Physicians, Psychiatrists, and Therapists.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of telemedicine and telepsychiatry services facilitating convenient treatment for generalized anxiety disorder
      • 5.1.1.2. Government initiatives and funding for mental health programs boosting market growth
      • 5.1.1.3. Integration of behavioral therapies and psychotherapies in treatment regimens enhancing patient outcomes
      • 5.1.1.4. Increasing collaborations between pharmaceutical companies and research institutions to develop advanced treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited insurance coverage and reimbursement issues affecting access to generalized anxiety disorder treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in pharmacological treatments for generalized anxiety disorder yielding high market potential
      • 5.1.3.2. Exploration of mindfulness and cognitive-behavioral therapy apps targeting anxiety disorders
      • 5.1.3.3. Increasing investment in mental health awareness campaigns driving market growth in anxiety-related products
    • 5.1.4. Challenges
      • 5.1.4.1. Social stigma surrounding mental health conditions impacting patient diagnosis and treatment-seeking behavior
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generalized Anxiety Disorder Market, by Mode Of Action

  • 6.1. Introduction
  • 6.2. Gamma-Aminobutyric Acid (GABA) Receptors
  • 6.3. Norepinephrine Modulators
  • 6.4. Serotonin Modulators

7. Generalized Anxiety Disorder Market, by Pricing Strategy

  • 7.1. Introduction
  • 7.2. Economy Pricing
  • 7.3. Penetration Pricing
  • 7.4. Premium Pricing

8. Generalized Anxiety Disorder Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Generalized Anxiety Disorder Market, by Healthcare Providers

  • 9.1. Introduction
  • 9.2. Primary Care Physicians
  • 9.3. Psychiatrists
  • 9.4. Therapists

10. Americas Generalized Anxiety Disorder Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generalized Anxiety Disorder Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generalized Anxiety Disorder Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkermes plc
  • 3. Allergan plc
  • 4. AstraZeneca plc
  • 5. Bristol-Myers Squibb Company
  • 6. Eli Lilly and Company
  • 7. GlaxoSmithKline plc
  • 8. H. Lundbeck A/S
  • 9. Jazz Pharmaceuticals plc
  • 10. Johnson & Johnson
  • 11. Merck & Co., Inc.
  • 12. Novartis International AG
  • 13. Otsuka Holdings Co., Ltd.
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi S.A.
  • 17. Sun Pharmaceutical Industries Ltd.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GENERALIZED ANXIETY DISORDER MARKET RESEARCH PROCESS
  • FIGURE 2. GENERALIZED ANXIETY DISORDER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERALIZED ANXIETY DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERALIZED ANXIETY DISORDER MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GAMMA-AMINOBUTYRIC ACID (GABA) RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY NOREPINEPHRINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SEROTONIN MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ECONOMY PRICING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PENETRATION PRICING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PREMIUM PRICING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRIMARY CARE PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PSYCHIATRISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 191. GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023